FDA Drug Shortages

Current and Resolved Drug Shortages and Discontinuations Reported to FDA

Start Over | Back to Previous Screen

Methylphenidate Hydrochloride (QUILLIVANT XR) for Extended-Release Oral Suspension
Status: Currently in Shortage
»Date first posted: 01/22/2018
»Therapeutic Categories: Pediatric; Psychiatry

Expand all

Tris Pharma, Inc. (Reverified 08/09/2019)

Company Contact Information:
732-940-0358

Presentation Availability and Estimated Shortage Duration Related Information Shortage Reason (per FDASIA)
300 mg/60 mL (NDC 24478-321-02) Available Effective September 21, 2018, Tris Pharma, Inc. acquired NextWave Pharmaceuticals, previously a wholly owned subsidiary of Pfizer Inc., including this product

Dear Health Care Provider Letter

Other
600 mg/120mL (NDC 24478-322-04) Available Effective September 21, 2018, Tris Pharma, Inc. acquired NextWave Pharmaceuticals, previously a wholly owned subsidiary of Pfizer Inc., including this product

Dear Health Care Provider Letter

Other
750 mg/150 mL (NDC 24478-323-05) Available Effective September 21, 2018, Tris Pharma, Inc. acquired NextWave Pharmaceuticals, previously a wholly owned subsidiary of Pfizer Inc., including this product

Dear Health Care Provider Letter

Other
900 mg/180 mL (NDC 24478-324-06) Available Effective September 21, 2018, Tris Pharma, Inc. acquired NextWave Pharmaceuticals, previously a wholly owned subsidiary of Pfizer Inc., including this product

Dear Health Care Provider Letter

Other

Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Language Assistance Available: Español | 繁體中文 | Tiếng Việt | 한국어 | Tagalog | Русский | العربية | Kreyòl Ayisyen | Français | Polski | Português | Italiano | Deutsch | 日本語 | فارسی | English